1. VHL and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications
   Lucy Gossage, 2015, Renal Cell Carcinoma CrossRef
2. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma
   Lucy Gossage et al, 2014, Genes, Chromosomes and Cancer CrossRef
3. The von Hippel–Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform
   F Chesnel et al, 2015, British Journal of Cancer CrossRef
4. Spectrum of VHL mutations in clear cell renal cell carcinoma
   N. N. Mazurenko et al, 2020, Advances in Molecular Oncology CrossRef
5. The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes includingTGFB1andMMP13
   Pauline Hascoet et al, 2017, Oncotarget CrossRef
6. Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma
   Lucile Broncy et al, 2018, Oncotarget CrossRef
7. Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism
   David Danielpour et al, 2022, Current Research in Pharmacology and Drug Discovery CrossRef
8. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance
   Caroline Razafinjatovo et al, 2016, BMC Cancer CrossRef
9. Autologous Islet Transplantation After Total Pancreatectomy for Renal Cell Carcinoma Metastases
   B.L. Gala-Lopez et al, 2013, American Journal of Transplantation CrossRef
10. Synonymous but Not Silent: A Synonymous VHL Variant in Exon 2 Confers Susceptibility to Familial Pheochromocytoma and von Hippel-Lindau Disease
    Shahida K Flores et al, 2019, The Journal of Clinical Endocrinology & Metabolism CrossRef